Sławomira Kyrcz‐Krzemień

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson et al. · Leukemia · 2021 · 332 citations · Full text

Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study

Jerzy Hołowiecki, Sebastian Grosicki, Sebastian Giebel et al. · Journal of Clinical Oncology · 2012 · 258 citations · Full text

Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis

Almalina Bacigalupo, Gèrard Socié, Rose Marie Hamladji et al. · Haematologica · 2015 · 170 citations · Full text

Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G‐CSF (CLAG‐M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group

Agnieszka Wierzbowska, Tadeusz Robak, Agnieszka Pluta et al. · European Journal Of Haematology · 2007 · 142 citations · Full text

Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study

Sebastian Grosicki, Tadeusz Robak, Sławomira Kyrcz‐Krzemień et al. · Leukemia · 2004 · 125 citations · Full text

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +8